4-Ipomeanol

Last updated
4-Ipomeanol
4-Ipomeanol.svg
4-Ipomeanol
Names
IUPAC name
1-(Furan-3-yl)-4-hydroxypentan-1-one
Identifiers
3D model (JSmol)
ChemSpider
PubChem CID
UNII
  • InChI=1S/C9H12O3/c1-7(10)2-3-9(11)8-4-5-12-6-8/h4-7,10H,2-3H2,1H3; Key: RJYQLMILDVERHH-UHFFFAOYSA-N
  • CC(CCC(=O)C1=COC=C1)O
Properties
C9H12O3
Molar mass 168.192 g·mol−1
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).

4-Ipomeanol (4-IPO) is a pulmonary pre-toxin isolated from sweet potatoes infected with the fungus Fusarium solani . [1] One of the 4-IPO metabolites is toxic to the lungs, liver and kidney in humans and animals. This metabolite can covalently bind to proteins, thereby interfering with normal cell processes. [2]

Contents

The toxic metabolite, an enedial, is mostly formed in the bronchiolar exocrine cells (club cells) in the lungs of rodents. Necrosis of bronchiolar cells is therefore the primary damaging effect of the toxin, due to this location of metabolism. The secondary pathological effects are edema, congestion and hemorrhage caused by the destruction of the bronchiolar exocrine cells. [3] In humans the metabolite is mostly formed in the liver, and causes liver toxicity. [3]

Structure and reactivity

4-Ipomeanol is a chemical compound belonging to the family of furans. It consists of a furan ring, which is substituted at the third carbon of the furan ring with a pentanone containing a hydroxyl group. A furan ring is a five-membered aromatic ring consisting of one oxygen atom and four carbon atoms; a pentanone is a ketone consisting of five carbon atoms. Other 3-substituted furans are ipomeanine (IPN), 1-ipomeanol (1-IPO) and 1,4-ipomeanol (DIOL), differing in the locations of the hydroxyl groups. [4] 4-IPO has three functional groups which determine the molecule's reactivity. These are the furan ring, the ketone group and the alcohol group.

Reactivity of furan ring

The furan ring is aromatic according to Hückel’s rule, so the furan makes the compound relatively stable. Therefore, this ring will not react easily with other compounds. Furan is heterocyclic, which means that it is cyclic, but one or more of the ring atoms is not a carbon atom. In the case of furan this heteroatom is an oxygen atom. This atom is sp2 hybridized and has one lone pair in an sp2 orbital and a second lone pair in a p orbital, overlapping with the p orbitals of adjacent carbons. This results in a pi bond formation. [5]

Reactivity of ketone

A ketone group is polar, as oxygen is more electronegative than carbon. Therefore, the carbonyl atom of the ketone group is electron deficient, thus electrophilic, and can easily react with nucleophiles. However, it does not undergo substitution reactions, as the attached molecule is a too strong base to be eliminated. As a result of this, irreversible nucleophilic addition reactions are possible: a nucleophile can add to the carbonyl carbon, but due to the lack of a good leaving group, no base is eliminated. This intermediate molecule takes up a proton, so a hydroxyl group is formed. When there is sufficient acid present, the hydroxyl group can be protonated further, making it a good leaving group. This functional group will then react as an alcohol group.

As described above is the basic reaction mechanism of ketones. In this way ketones can undergo several organic reactions, reacting with compounds like grignard reagents, acetylide, cyanide, and hydride ions, amines, water, alcohols and peroxyacids. [5]

Reactivity of alcohol

The alcohol group is a strongly basic leaving group that cannot undergo nucleophilic substitution reactions. However, it becomes a better leaving group after protonation, which converts the leaving group from OH− to H2O. H2O is a weaker base than OH− and can thus undergo substitution reactions with weakly basic nucleophiles. This reaction occurs following a SN2 mechanism, as 4-IPO is a secondary alcohol.

Dehydration of the at the pentanone substituted alcohol group is also possible, following an E1 reaction mechanism. This reaction is acid-catalyzed and results in the loss of a water molecule. Like with the SN1 reaction, protonation of the leaving group is required first. Water then is eliminated, leaving behind a carbocation, which leads eventually to alkene formation. Furthermore, secondary alcohols can undergo oxidation reactions. This results in the formation of a ketone. [5]

Synthesis

Synthesis of 4-IPO Synthese of 4-IPO.jpg
Synthesis of 4-IPO

4-IPO can be isolated from sweet potatoes infected with the fungus Fusarium solani. [1] However, it can also be synthesized from the commercially available chemical diethyl 3,4-furandicarboxylate.

Partial hydrolysis of diethyl 3,4-furandicarboxylate (I) with an equimolar quantity of NaOH results in the monoester 4-(ethoxycarbonyl)furan-3-carboxylic acid (II) occurs. This is followed by decarboxylation by heating with a copper powder yielded ethyl 3-furoate (III). The Claisen condensation is used to form ethyl 3-furoylacetate (IV). By reacting with propylene oxide, lactone (V) is formed. Decarboxylation is achieved by gently heating lactone in the presence of diluted acid (VI). [7]

Metabolism

Metabolic activation of 4-IPO occurs by one of the enzymes of the cytochrome P450 (CYP) superfamily. The oxidation of the furan ring leads to the formation of an unstable epoxide (cyclic ester with a three-atom ring), so an alkylating intermediate species, 4-IPO enedial, is formed. [3]

In rodents it is CYP4B1 that activates 4-IPO [1], an enzyme of the CYP4 family, of which the CYP4B subfamily is involved in the fatty acid metabolism. [8] CYP4B1 is present in high levels in the lungs and its affinity for 4-IPO is greater than for liver CYP enzymes. Therefore, the activated form of 4-IPO is mainly toxic to the lungs in rodents. [3]

Schematic illustrating bioactivation versus inactivation routes for 4-IPO after either P450- or uridine 5'-diphospho-glucuronosyltransferase-mediated metabolism Phase I and II.jpg
Schematic illustrating bioactivation versus inactivation routes for 4-IPO after either P450- or uridine 5′-diphospho-glucuronosyltransferase-mediated metabolism

However, in humans the reactivity of CYP4B1 is different and it does not activate 4-IPO. The CYP enzymes CYP1A2 and CYP3A4 are active in the liver and are similar to the rodent CYP4B1. 4-IPO is thus metabolically activated by CYP1A2 and CYP3A4 in humans. These two enzymes are both part of several pathways involved in the drug metabolism. [3] As both CYPs are mainly active in the liver, 4-IPO causes hepatotoxicity in humans. [4]

In both rodents and humans phase I metabolism involves the biotransformation of 4-IPO into an epoxide intermediate by CYPs. This epoxide is unstable, so it degrades into an enedial intermediate. The enedial intermediate is toxic, as it can bind to proteins. However, it can be detoxified in phase II metabolism, in which the enedial can be conjugated with either N-acetyl lysine (NAL) or N-acetyl cysteine (NAC). This results in a NAL/NAC-IPO adduct, which can be excreted. Furthermore, 4-IPO can directly undergo phase II metabolism, by conjugating glucuronosyl to the hydroxyl group of 4-IPO by uridine 5’-diphospho-glucuronosyltransferase (UGT), forming 4-IPO glucuronide. This can, like the NAL/NAC-IPO adduct, be excreted. However, the major pathway involves the enedial intermediate and the NAL/NAC-IPO adduct is the major product of biotransformation. [10]

In contrast with these findings of in vivo studies, several other pathways for biotransformation of 4-IPO are found in vitro.

In vitro microsomal incubation of 4-IPO and its GSH adducts as products Products formed by 4-IPO.tiff
In vitro microsomal incubation of 4-IPO and its GSH adducts as products

Next to oxidation of the furan ring of 4-IPO, so that the 4-IPO enedial is formed, the hydroxyl group of 4-IPO can be oxidized. Oxidation of this functional group leads to ketone formation, so IPN is formed. IPN can undergo oxidation of the furan ring by CYPs, like 4-IPO. After this bioactivation reaction, the product can be conjugated to glutathione (GSH) by glutathione-S-transferase (GST). Furthermore, 4-IPO can be reduced and DIOL is the product of this biotransformation. Finally, 4-IPO can interact with [[NADP+]], forming a molecule which contains 4-IPO and NADPH. Of these four pathways described, the oxidation to IPN and the reduction to DIOL are the major processes. [4]

Next to the difference in possible metabolic reactions 4-IPO can undergo, there is also a difference in the metabolization of the reactive 4-IPO enedial. This compound can be metabolized by either UGT [10] or GSH. [4] Metabolization by UGT results in NAL/NAC-IPO adducts, [10] while multiple products can be the result of GSH metabolism. Interaction of the 4-IPO enedial with GSH leads both to a Michael adduct and a dihydrohydroxyfuran adduct. The Michael adduct is the product of a Michael addition (1,4-addition of a cysteine), of the cysteine in GSH at the 4-position of the enedial. This Michael adduct can undergo dehydration and forms, via a tricyclic 2’-pyrroline adduct (14), a mono-GSH pyrrole adduct (16). Another reaction the Michael adduct can undergo is again dehydration and conjugation with GSH. Via the formation of subsequently an imine, enamine and an iminium ion, a bis-GSH pyrrole adduct (18) is formed. Another reaction via which the Michael adduct can form a bis-GSH pyrrole adduct (20), is firstly by undergoing elimination of a ketone group, followed by again dehydration in combination with GSH conjugation. [4]

The dihydrohydroxyfuran adduct can also undergo dehydration in combination with GSH conjugation in a similar way as the Michael adduct, which results in a bis-GSH pyrrole adduct (19). Furthermore, the dihydrohydroxyfuran can dehydrate and form a mono-GSH pyrrole adduct (17). [4]

Pharmacological use

Distribution of 4-IPO across tissues shows the same patterns for intravenous, oral and intraperitoneal injection and peak concentrations are achieved one to two hours after administration. By then most of the 4-IPO will be located in the lungs, followed by liver, kidney and blood. Apart from having the highest 4-IPO concentration, lung cells also show the highest level of covalently bound 4-IPO. This is in contrast with the gut, where the most occurring form of 4-IPO is unbound. After four hours 4-IPO levels show a plateau which persists for 24 hours. 4-IPO molecules still present at that time are mostly bound to other macromolecules. [11] The IC50 was determined by an automated cell culture growth inhibition assay which shows IC50 ranging from 2-8 mM, depending on the cell type. [12] The IC50 was also determined by another group which found roughly the same. [13]

Detoxification is suspected to occur primarily via glucuronidation of 4-IPO. Out of all the metabolites found in urine, the primary excretion pathway, 4-IPO glucuronide was the most abundant. Excretion of 4-IPO glucuronide can be increased when rats were treated with phenobarbital, which increases γ-aminobutyric acid (GABA) activity. [11]

Half-life varies from species to species. In mice the half-life is approximately 33 minutes after intravenous injection of 20 mg/kg 4-IPO. This is lower in rats and dogs. Rats need around six minutes to reduce the 4-IPO concentration by half and dogs around ten minutes. Both were administered a single intravenous dose of 6 mg/kg. [11]

Preclinical trials

Several in vitro experiments were performed to explore the possible uses of 4-IPO, which showed promising results. Different lung, ovarian, breast and melanoma cancer cell lines showed apoptosis or inhibited tumor growth when exposed to high levels of 4-IPO (100 ug/uL). These results could not be replicated in conventional cancer screens, probably due to the fact that 4-IPO metabolism relies on very specific enzymes and environments which could not be replicated by conventional screens. However, 4-IPO showed effects when exposed to human lung cell lines. Four cell lines were tested and two showed inhibited tumor growth. Both cell lines were non-small cell lung carcinoma, while the two cell lines with no effects were small cell tumors. Other experiments showed that 4-IPO reduced tumor growth in a microencapsulated tumor assay at a concentration of 25 mg/mL. Furthermore, covalent binding of 4-IPO intermediates was observed in fresh lung biopsies. [11]

Phase I Trial

On the basis of this knowledge a phase I trial was performed to study the effects of 4-IPO on the human body. 34 men and 10 women with non-small cell lung cancer were tested. The trial showed no significant hematological or renal toxicity but also no effect on the tumor. Measurements with biopsies obtained from the patients showed an IC50 of 6 mM, which is around 75 times higher than the measured plasma concentrations [13] and likely higher than the plasma concentration achievable in vivo. [12]

Phase II Trial

An earlier phase I and pharmacological trial showed that hepatotoxicity is dose limiting in humans and not lung toxicity. [12] Based on these results a phase II trial was conducted to test the effects of 4-IPO on patients with advanced measurable hepatocellular carcinoma. Nineteen patients were treated with 1032 mg/m2 4-IPO. One patient showed a brief reduction in metastasis in the lung, but the rest showed no significant effects. As a consequence the authors recommend that 4-IPO is not used for further testing. [14]

Further use in cancer treatment

Recently 4-IPO has been used in experiments where it plays a role in T-cell therapy. Autologous T-cells can be altered to express tumor specific antigens. These cells will then bind to tumors and induce apoptosis. There are side-effects associated with this kind of treatment and 4-IPO can help to control those side effects. A suicide gene is needed to induce apoptosis in T-cells when needed. CYP4B1 is inactive in humans but with minor changes in the amino acid sequence it can be activated again. This would result in T-cell death when the cells are exposed to 4-IPO, because they metabolize 4-IPO efficiently. [15] [16] Non toxic 4-IPO analogues are also capable of inhibiting nicotine-derived nitrosamine ketone (NNK) metabolism. NNK is a pre-carcinogen which is activated inside the lung. Out of the four analogues tested (4-hydroxy-lphenyl-1-pentanone (HPP); 7-hydroxy-1-phenyl-1-octanone (HPO); 4-hydroxy-1- (2-thienyl)-1-pentanone (HTP); 4-hydroxy-l-(3-pyridyl)-l-pentanone (HPYP)) HPP and HPO showed competitive and noncompetitive inhibition of NNK and it reduces tumor formation in mice. [1]

Toxicity

4-IPO is a specific lethal toxicant which mainly targets bronchiolar exocrine cells in the smaller bronchioles of rodent and cattle lungs. With an increased dose it is also possible to affect other cells and the airway of organisms. Covalent binding of 4-IPO to members of the CYP family (mainly CYP4B1) eventually leads to biotransformation of 4-IPO into an enedial intermediate, which is able to bind to a variety of proteins. These binding events are permanent and responsible for 4-IPO toxicity. [10] This will result in cytotoxicity and eventually necrosis of bronchiolar exocrine cells, while ciliated bronchiolar cells and other epithelial lung cells are not affected, due to lower levels of cytochrome proteins. [3] Necrotic patches, also called lesions or primary pathological changes, can develop into edemas, resulting in thickening of the alveolar septum, [17] congestion, and hemorrhage (secondary and tertiary pathological changes). [3] Lethality is probably due to pulmonary edema. Prior to death the dogs also showed rapid and shallow respiration, while in rats labored respiration and lymphocyte depletion can be observed. The LD50 dose varies between different species. In female mice 21 mg/kg/day 4-IPO are sufficient while in male mice 35 mg/kg/day were necessary. 15 mg/kg 4-IPO intravenously administered into rats is lethal and in dogs this dose is 12 mg/kg. It is possible to increase the LD50 by 2–4.5 fold when individuals are treated with multiple non-toxic doses beforehand. [18]

In humans, 4-IPO shows minimal effects in the lung because the enzymes needed for biotransformation of 4-IPO are not present. Instead the liver is affected, because human liver cells do contain enzymes to biotransform 4-IPO. Something similar can be observed in male mice. Apart from the effects seen in the lungs they also have certain enzymes in their kidney which can transform 4-IPO into its reactive intermediate. As a result, renal toxicity is observed. Female mice and immature male mice do not have these enzymes. Therefore, they are resistant to renal toxicity. [2]

Effects on animals

4-IPO has, similar to humans, a toxic effect on animals. It is toxic to livestock and many laboratory animals. [10] Male rabbits, mice, rats and hamsters were used to test the effect of 4-IPO on. In all four species, the lung was a major target. In the hamsters and mice additional liver necrosis and renal necrosis, respectively, was detected. [2] 4-IPO can also threaten newborn calves. If they become exposed to 4-IPO it increases their susceptibility to bovine parainfluenza virus 3. Parainfluenza itself does not have severe health effects but together with other infections it can lead to complex enzootic pneumonia. [19]

Related Research Articles

<span class="mw-page-title-main">Methylcholanthrene</span> Chemical compound

Methylcholanthrene is a highly carcinogenic polycyclic aromatic hydrocarbon produced by burning organic compounds at very high temperatures. Methylcholanthrene is also known as 3-methylcholanthrene, 20-methylcholanthrene or the IUPAC name 3-methyl-1,2-dyhydrobenzo[j]aceanthrylene. The short notation often used is 3-MC or MCA. This compound forms pale yellow solid crystals when crystallized from benzene and ether. It has a melting point around 180 °C and its boiling point is around 280 °C at a pressure of 80 mmHg. Methylcholanthrene is used in laboratory studies of chemical carcinogenesis. It is an alkylated derivative of benz[a]anthracene and has a similar UV spectrum. The most common isomer is 3-methylcholanthrene, although the methyl group can occur in other places.

Drug metabolism is the metabolic breakdown of drugs by living organisms, usually through specialized enzymatic systems. More generally, xenobiotic metabolism is the set of metabolic pathways that modify the chemical structure of xenobiotics, which are compounds foreign to an organism's normal biochemistry, such as any drug or poison. These pathways are a form of biotransformation present in all major groups of organisms and are considered to be of ancient origin. These reactions often act to detoxify poisonous compounds. The study of drug metabolism is called pharmacokinetics.

Toxication, toxification or toxicity exaltation is the conversion of a chemical compound into a more toxic form in living organisms or in substrates such as soil or water. The conversion can be caused by enzymatic metabolism in the organisms, as well as by abiotic chemical reactions. While the parent drug are usually less active, both the parent drug and its metabolite can be chemically active and cause toxicity, leading to mutagenesis, teratogenesis, and carcinogenesis. Different classes of enzymes, such as P450-monooxygenases, epoxide hydrolase, or acetyltransferases can catalyze the process in the cell, mostly in the liver.

<span class="mw-page-title-main">Sudan I</span> Chemical compound

Sudan I, is an organic compound, typically classified as an azo dye. It is an intensely orange-red solid that is added to colourise waxes, oils, petrol, solvents, and polishes. Sudan I has also been adopted for colouring various foodstuffs, especially curry powder and chili powder, although the use of Sudan I in foods is now banned in many countries, because Sudan I, Sudan III, and Sudan IV have been classified as category 3 carcinogens by the International Agency for Research on Cancer. Sudan I is still used in some orange-coloured smoke formulations and as a colouring for cotton refuse used in chemistry experiments.

4-Aminobiphenyl (4-APB) is an organic compound with the formula C6H5C6H4NH2. It is an amine derivative of biphenyl. It is a colorless solid, although aged samples can appear colored. 4-Aminobiphenyl was commonly used in the past as a rubber antioxidant and an intermediate for dyes. Exposure to this aryl-amine can happen through contact with chemical dyes and from inhalation of cigarette smoke. Researches showed that 4-aminobiphenyl is responsible for bladder cancer in humans and dogs by damaging DNA. Due to its carcinogenic effects, commercial production of 4-aminobiphenyl ceased in the United States in the 1950s.

The glyoxalase system is a set of enzymes that carry out the detoxification of methylglyoxal and the other reactive aldehydes that are produced as a normal part of metabolism. This system has been studied in both bacteria and eukaryotes. This detoxification is accomplished by the sequential action of two thiol-dependent enzymes; firstly glyoxalase І, which catalyzes the isomerization of the spontaneously formed hemithioacetal adduct between glutathione and 2-oxoaldehydes into S-2-hydroxyacylglutathione. Secondly, glyoxalase ІІ hydrolyses these thiolesters and in the case of methylglyoxal catabolism, produces D-lactate and GSH from S-D-lactoyl-glutathione.

Pharmacotoxicology entails the study of the consequences of toxic exposure to pharmaceutical drugs and agents in the health care field. The field of pharmacotoxicology also involves the treatment and prevention of pharmaceutically induced side effects. Pharmacotoxicology can be separated into two different categories: pharmacodynamics, and pharmacokinetics.

<span class="mw-page-title-main">Chlorethoxyfos</span> Chemical compound

Chlorethoxyfos is an organophosphate acetylcholinesterase inhibitor used as an insecticide. It is registered for the control of corn rootworms, wireworms, cutworms, seed corn maggot, white grubs and symphylans on corn. The insecticide is sold under the trade name Fortress by E.I. du Pont de Nemours & Company.

<span class="mw-page-title-main">Hexachlorocyclopentadiene</span> Chemical compound

Hexachlorocyclopentadiene (HCCPD), also known as C-56, Graphlox, and HRS 1655, is an organochlorine compound with the formula C5Cl6. It is a precursor to pesticides, flame retardants, and dyes. It is a colourless liquid, although commercial samples appear lemon-yellow liquid sometimes with a bluish vapour. Many of its derivatives proved to be highly controversial, as studies showed them to be persistent organic pollutants. An estimated 270,000 tons were produced until 1976, and smaller amounts continue to be produced today. Two prominent manufacturers are Velsicol Chemical Corporation in the US and by Jiangsu Anpon Electrochemicals Co. in China.

<span class="mw-page-title-main">2-Acetylaminofluorene</span> Chemical compound

2-Acetylaminofluorene is a carcinogenic and mutagenic derivative of fluorene. It is used as a biochemical tool in the study of carcinogenesis. It induces tumors in a number of species in the liver, bladder and kidney. The metabolism of this compound in the body by means of biotransformation reactions is the key to its carcinogenicity. 2-AAF is a substrate for cytochrome P-450 (CYP) enzyme, which is a part of a super family found in almost all organisms. This reaction results in the formation of hydroxyacetylaminofluorene which is a proximal carcinogen and is more potent than the parent molecule. The N-hydroxy metabolite undergoes several enzymatic and non-enzymatic rearrangements. It can be O-acetylated by cytosolic N-acetyltransferase enzyme to yield N-acetyl-N-acetoxyaminofluorene. This intermediate can spontaneously rearrange to form the arylamidonium ion and a carbonium ion which can interact directly with DNA to produce DNA adducts. In addition to esterification by acetylation, the N-hydroxy derivative can be O-sulfated by cytosolic sulfur transferase enzyme giving rise to the N-acetyl-N-sulfoxy product.

<span class="mw-page-title-main">Senecionine</span> Chemical compound

Senecionine is a toxic pyrrolizidine alkaloid isolated from various botanical sources. It takes its name from the Senecio genus and is produced by many different plants in that genus, including Jacobaea vulgaris. It has also been isolated from several other plants, including Brachyglottis repanda, Emilia, Erechtites hieraciifolius, Petasites, Syneilesis, Crotalaria, Caltha leptosepala, and Castilleja.

<span class="mw-page-title-main">Microcystin-LR</span> Chemical compound

Microcystin-LR (MC-LR) is a toxin produced by cyanobacteria. It is the most toxic of the microcystins.

Methacrylonitrile, MeAN in short, is a chemical compound that is an unsaturated aliphatic nitrile, widely used in the preparation of homopolymers, copolymers, elastomers, and plastics and as a chemical intermediate in the preparation of acids, amides, amines, esters, and other nitriles. MeAN is also used as a replacement for acrylonitrile in the manufacture of an acrylonitrile/butadiene/styrene-like polymer. It is a clear and colorless liquid, that has a bitter almond smell.

Benzo(<i>c</i>)fluorene Chemical compound

Benzo[c]fluorene is a polycyclic aromatic hydrocarbon (PAH) with mutagenic activity. It is a component of coal tar, cigarette smoke and smog and thought to be a major contributor to its carcinogenic properties. The mutagenicity of benzo[c]fluorene is mainly attributed to formation of metabolites that are reactive and capable of forming DNA adducts. According to the KEGG it is a group 3 carcinogen. Other names for benzo[c]fluorene are 7H-benzo[c]fluorene, 3,4-benzofluorene, and NSC 89264.

<span class="mw-page-title-main">Glycidamide</span> Chemical compound

Glycidamide is an organic compound with the formula H2NC(O)C2H3O. It is a colorless, oil. Structurally, it contains adjacent amides and epoxide functional groups. It is a bioactive, potentially toxic or even carcinogenic metabolite of acrylonitrile and acrylamide. It is a chiral molecule.

<span class="mw-page-title-main">Lorlatinib</span> Kinase inhibitor for treatment of non-small-cell lung cancer

Lorlatinib, sold under the brand name Lorbrena in the United States, Canada, and Japan, and Lorviqua in the European Union, is an anti-cancer drug developed by Pfizer. It is an orally administered inhibitor of ALK and ROS1, two enzymes that play a role in the development of cancer.

<span class="mw-page-title-main">Hydroxylation of estradiol</span>

The hydroxylation of estradiol is one of the major routes of metabolism of the estrogen steroid hormone estradiol. It is hydroxylated into the catechol estrogens 2-hydroxyestradiol and 4-hydroxyestradiol and into estriol (16α-hydroxyestradiol), reactions which are catalyzed by cytochrome P450 enzymes predominantly in the liver, but also in various other tissues.

VEGFR-2 inhibitor, also known as kinase insert domain receptor(KDR) inhibitor, are tyrosine kinase receptor inhibitors that reduce angiogenesis or lymphangiogenesis, leading to anticancer activity. Generally they are small, synthesised molecules that bind competitively to the ATP-site of the tyrosine kinase domain. VEGFR-2 selective inhibitor can interrupt multiple signaling pathways involved in tumor, including proliferation, metastasis and angiogenesis.

<span class="mw-page-title-main">PR toxin</span> Chemical compound

Penicillin Roquefort Toxin is a mycotoxin produced by the fungi Penicillium roqueforti. In 1973, PR toxin was first partially characterized by isolating moldy corn on which the fungi had grown. Although its lethal dose was determined shortly after the isolation of the chemical, details of its toxic effects, were not fully clarified until 1982 in a study with mice, rats, anesthetized cats and preparations of isolated rat auricle.

<span class="mw-page-title-main">Monocrotaline</span> Chemical compound

Monocrotaline (MCT) is a pyrrolizidine alkaloid that is present in plants of the Crotalaria genus. These species can synthesise MCT out of amino acids and can cause liver, lung and kidney damage in various organisms. Initial stress factors are released intracellular upon binding of MCT to BMPR2 receptors and elevated MAPK phosphorylation levels are induced, which can cause cancer in Homo sapiens. MCT can be detoxified in rats via oxidation, followed by glutathione-conjugation and hydrolysis.

References

  1. 1 2 3 Lin JM, Desai DH, Morse MA, Amin S, Hecht SS. 1992. INHIBITION OF 4-(METHYLNITROSAMINO)-1-(3-PYRIDYL)-1-BUTANONE PULMONARY METABOLISM AND TUMORIGENICITY IN MICE BY ANALOGS OF THE INVESTIGATIONAL CHEMOTHERAPEUTIC DRUG 4-IPOMEANOL. Chemical Research in Toxicology 5(5):674-679.
  2. 1 2 3 Dutcher JS, Boyd MR. 1979. SPECIES AND STRAIN DIFFERENCES IN TARGET ORGAN ALKYLATION AND TOXICITY BY 4-IPOMEANOL - PREDICTIVE VALUE OF COVALENT BINDING IN STUDIES OF TARGET ORGAN TOXICITIES BY REACTIVE METABOLITES. Biochemical Pharmacology 28(23):3367-3372.
  3. 1 2 3 4 5 6 7 Timbrell J. 2009. Principles of Biochemical Toxicology.
  4. 1 2 3 4 5 6 Chen LJ, DeRose EF, Burka LT. 2006. Metabolism of furans in vitro: Ipomeanine and 4-ipomeanol. Chemical Research in Toxicology 19(10):1320-1329.
  5. 1 2 3 Bruice PY. 2013. Organic Chemistry. Pearson Education.
  6. 1 2 Chen, Ling-Jen; DeRose, Eugene F.; Burka, Leo T. (2006-10-01). "Metabolism of Furans in Vitro: Ipomeanine and 4-Ipomeanol". Chemical Research in Toxicology. 19 (10): 1320–1329. doi:10.1021/tx060128f. ISSN   0893-228X. PMID   17040101.
  7. ↑ BOYD MR, WILSON BJ, HARRIS TM. 1972. Confirmation by chemical synthesis of the structure of 4-ipomeanol, a lung-toxic metabolite of the sweet potato, Ipomoea batatas. Nature 236(66):158-159.
  8. ↑ Simpson A. 1997. The cytochrome P450 4 (CYP4) family. General Pharmacology-the Vascular System 28(3):351-359.
  9. ↑ Parkinson, Oliver T.; Teitelbaum, Aaron M.; Whittington, Dale; Kelly, Edward J.; Rettie, Allan E. (2016-10-01). "Species Differences in Microsomal Oxidation and Glucuronidation of 4-Ipomeanol: Relationship to Target Organ Toxicity". Drug Metabolism and Disposition. 44 (10): 1598–1602. doi:10.1124/dmd.116.070003. ISSN   0090-9556. PMC   5034698 . PMID   27468999.
  10. 1 2 3 4 5 Parkinson OT, Teitelbaum AM, Whittington D, Kelly EJ, Rettie AE. 2016. Species Differences in Microsomal Oxidation and Glucuronidation of 4-Ipomeanol: Relationship to Target Organ Toxicity. Drug Metabolism and Disposition 44(10):1598-1602.
  11. 1 2 3 4 Christian MC, Wittes RE, Leylandjones B, McLemore TL, Smith AC, Grieshaber CK, Chabner BA, Boyd MR. 1989. 4-IPOMEANOL - A NOVEL INVESTIGATIONAL NEW DRUG FOR LUNG-CANCER. Journal of the National Cancer Institute 81(15):1133-1143.
  12. 1 2 3 Rowinsky EK, Noe DA, Ettinger DS, Christian MC, Lubejko BG, Fishman EK, Sartorius SE, Boyd MR, Donehower RC. 1993. PHASE-I AND PHARMACOLOGICAL STUDY OF THE PULMONARY CYTOTOXIN 4-IPOMEANOL ON A SINGLE DOSE SCHEDULE IN LUNG-CANCER PATIENTS - HEPATOTOXICITY IS DOSE LIMITING IN HUMANS. Cancer Research 53(8):1794-1801.
  13. 1 2 Kasturi VK, Dearing MP, Piscitelli SC, Russell EK, Sladek GG, O'Neil K, Turner GA, Morton TL, Christian MC, Johnson BE et al. . 1998. Phase I study of a five-day dose schedule of 4-ipomeanol in patients with non-small cell lung cancer. Clinical Cancer Research 4(9):2095-2102.
  14. ↑ Lakhanpal S, Donehower RC, Rowinsky EK. 2001. Phase II study of 4-ipomeanol, a naturally occurring alkylating furan, in patients with advanced hepatocellular carcinoma. Investigational New Drugs 19(1):69-76.
  15. ↑ Hanenberg H, Roellecke K, Wiek C. 2017. CYP4B1 as a Novel Suicide Gene in Cancer Therapy. Drug Metabolism and Pharmacokinetics 32(1):S8-S9.
  16. ↑ Roellecke K, Virts EL, Einholz R, Edson KZ, Altvater B, Rossig C, von Laer D, Scheckenbach K, Wagenmann M, Reinhardt D et al. . 2016. Optimized human CYP4B1 in combination with the alkylator prodrug 4-ipomeanol serves as a novel suicide gene system for adoptive T-cell therapies. Gene Therapy 23(7):615-626.
  17. ↑ Verschoyle RD, Philpot RM, Wolf CR, Dinsdale D. 1993. CYP4B1 ACTIVATES 4-IPOMEANOL IN RAT LUNG. Toxicology and Applied Pharmacology 123(2):193-198.
  18. ↑ Smith AC, Barrett D, Stedham MA, Elhawari M, Kastello MD, Grieshaber CK, Boyd MR. 1987. PRECLINICAL TOXICOLOGY STUDIES OF 4-IPOMEANOL - A NOVEL CANDIDATE FOR CLINICAL-EVALUATION IN LUNG-CANCER. Cancer Treatment Reports 71(12):1157-1164.
  19. ↑ Li X, Castleman WL. 1991. EFFECTS OF 4-IPOMEANOL ON BOVINE PARAINFLUENZA TYPE-3 VIRUS-INDUCED PNEUMONIA IN CALVES. Veterinary Pathology 28(5):428-437.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.